Biocircuits: Market Realities, Technology Commitments
Biocircuits was failing along with its breakthrough diagnostics invention until it saw that its raison d’etre was a marketplace, not a technology. That understanding allowed it to see other ways to make its projects into commercial realities. Instead of risking its remaining money on perfecting its breakthrough but intractable technology, it has switched to working on a product based on traditional technology. But Biocircuits' delays have cost it a major market opportunity and forced it to confront, at product launch, a marketplace in the process of radical transformation.
You may also be interested in...
The Centers for Medicare and Medicaid Services has agreed to provide national Medicare coverage for mitral valve transcatheter edge-to-edge repair under a new coverage with evidence development policy. See what Neil Moat, chief medical officer for Abbott’s structural heart business, said about it here.
South Korea’s Ministry of Food and Drug Safety and Taiwan’s Food and Drug Administration will transition from ICCR observers to full members, joining regulatory authorities from the US, Europe, Japan, Canada and Brazil. PCPC’s Francine Lamoriello, EVP of global affairs, discusses.
If Biden administration wants to nominate the acting commissioner, Vacancies Reform Act would dictate the timing. Woodcock can still get the nod and remain head of the agency during the confirmation process, just as Andrew von Eschenbach retained his acting title following his nomination in 2006.